CD84 deficiency also disrupted the leukemogenic potential of inv(16) AML cells, decreasing by more than 80% the leukemic engraftment in the BM (P < 0.0001), SP (P = 0.004), and PB (P = 0.014) of recipients (Figure 5, D and E, and Supplemental Figure 4M), leading to a substantial reduction in SP weight (Supplemental Figure 4, N and O), compared with mice carrying leukemia cells with intact CD84 expression. This evidence concerns the gene CD84 and acute myeloid leukemia.